On April 3, 2026, Vivos Therapeutics, Inc. announced the completion of a private investment in public equity (PIPE) offering, securing $850,000 in cash proceeds. The company entered into a Securities Purchase Agreement (PIPE SPA) with V-Co Investors 3 LLC, an affiliate of New Seneca Partners Inc., a prominent private equity firm. Under the terms of the PIPE SPA, Vivos sold 1,353,625 shares of common stock and issued a pre-funded warrant for an additional 429,957 shares. The offering also included Series A and Series B common stock purchase warrants, each allowing the purchase of up to 1,783,582 shares at an exercise price of $1.09 per share. The funds raised will be utilized for general working capital purposes. The PIPE offering closed on March 31, 2026, and the company is required to file a registration statement for the resale of the shares and warrants within 45 days. This strategic move is expected to enhance Vivos' liquidity position and support its operational initiatives.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.